Study finds Paxlovid ineffective for treating long Covid

A recent study reported that the antiviral Paxlovid did not provide measurable benefit for patients suffering from long Covid symptoms. Researchers observed no significant improvement compared with standard care, suggesting the drug may not be useful for this condition.

The findings contrast with earlier hopes that Paxlovid could help mitigate lingering effects of COVID-19, and they add to the growing body of evidence evaluating post-acute treatments.

In the same briefing, the administration announced new drug-pricing agreements involving nine additional companies. The deals aim to align U.S. drug prices with those in peer nations and include provisions for Medicaid pricing and domestic manufacturing support.

Details of the pricing arrangements were not disclosed, leaving analysts to await further information on their impact on Medicare and overall drug costs.